Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences

On May 2, 2019 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, MAY 2, 2019, View Source [SID1234535572]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America Merrill Lynch 2019 Health Care Conference– Las Vegas, May 14-16, 2019
May 15, 8:40 a.m. PDT –Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will deliver a corporate presentation

Vascular Discovery: From Genes to Medicine 2019 Scientific Sessions (ATVB|PVD) – Boston,
May 14-16, 2019 May 15, 11:00 a.m. EDT – So Wong, Ph.D., Arrowhead’s director of biology, will deliver a poster presentation titled, "Reduction in Angiopoietin-Like Protein 3 via RNA Interference Improves Dyslipidemias and Hepatic Steatosis"

2019 National Lipid Association Scientific Sessions – Aventura, FL,
May 16-19, 2019 May 18, 11:25 a.m. EDT – So Wong, Ph.D., Arrowhead’s director of biology, will deliver a poster presentation titled, "Personalized Medicine for Dyslipidemias by RNA Interference-Mediated Reductions in Apolipoprotein C3 or Angiopoietin-Like Protein 3"

20th Annual B. Riley FBR Institutional Investor Conference– Beverly Hills, May 22-23, 2019
May 23, 8:30 a.m. PDT –Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will participate in a fireside chat presentation with Mayank Mamtani, B. Riley FBR research analyst

A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019

On May 2, 2019 Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, reported that the Company will host a conference call and webcast on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2019 (Press release, Verastem, MAY 2, 2019, View Source;p=irol-newsArticle&ID=2396781 [SID1234535571]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315) 625-3226 (international), five minutes prior to the start of the call and providing the passcode 7199457. The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company’s website at www.verastem.com. A replay of the webcast will be archived on the Company’s website for 90 days following the call.

Iovance Biotherapeutics to Participate in Upcoming Conferences in May

On May 2, 2019 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that the company plans to participate in the following conferences in May (Press release, Iovance Biotherapeutics, MAY 2, 2019, View Source;p=irol-newsArticle&ID=2396790 [SID1234535570]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NYAS Frontiers in Cancer Immunotherapy in New York, May 14-15, 2019
Panel Presentation: Will CAR-T Cell Therapies, Bispecific Antibodies, or TILs Be More Beneficial for Solid Tumors?
Session: Session 4, Breakout Track B
Location: The New York Academy of Sciences
Date/time: Wednesday, May 15, at 1:00 p.m. EDT

Oppenheimer Oncology Insight Summit in New York, May 16, 2019
Location: InterContinental New York Barclay Hotel

AACR Bladder Cancer: Transforming the Field Conference in Denver, May 18-21, 2019
Poster Presentation: Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from advanced bladder cancer for adoptive immunotherapy
Authors: Qiang John Li et al.
Session Type: Poster Session A
Abstract Number: A05
Location: Grand Hyatt Denver
Date/Time: Sunday, May 19, from 12:30 p.m. – 3:00 p.m. MDT

20th Annual B. Riley FBR Investor Conference in Beverly Hills, CA, May 22-23, 2019
Location: The Beverly Hilton Hotel
Date/Time: Thursday, May 23, at 9:00 a.m. PDT
A live and archived webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics’ website at View Source

Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019

On May 2, 2019 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that it will report first quarter 2019 financial results on Thursday, May 9, 2019 (Press release, Karyopharm, MAY 2, 2019, View Source [SID1234535569]). Karyopharm’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 9, 2019 to discuss the financial results and other company updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least 10 minutes prior to the start time and refer to conference ID 9756776. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company’s website, View Source An archived webcast will be available on the Company’s website approximately two hours after the event.

Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call

On May 2, 2019 Spectrum Pharmaceuticals (NasdaqGS: SPPI), reported it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company’s business, and discuss expectations for the future on Thursday, May 9, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific (Press release, Spectrum Pharmaceuticals, MAY 2, 2019, View Source [SID1234535568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call

Thursday, May 9, 2019 @ 4:30 p.m. Eastern/1:30 p.m. Pacific

Domestic:
(877) 837-3910, Conference ID# 4290388

International:

(973) 796-5077, Conference ID# 4290388

For interested individuals unable to join the call, a replay will be available from May 9, 2019 @ 7:30 p.m. ET/4:30 p.m. PT through May 16, 2019 until 11:59 p.m. ET/8:59 p.m. PT.


Domestic Replay Dial-In #:

(855) 859-2056, Conference ID# 4290388
International Replay Dial-In #:

(404) 537-3406, Conference ID# 4290388
This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals’ website: View Source on May 9, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.